Seeing more than ever before

A highly sensitive liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.

Lymphoma assay extensively validated in hundreds of patients with B-cell malignancies

Detect relapse 200+ days earlier By detecting 1 part per million

See what others miss

Latest Updates

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

May 30, 2023

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma

Download Paper

Apr 27, 2023

Foresight Diagnostics' approach for the earlier detection of cancer recurrence pulls in nearly $59M

Apr 27, 2023

Foresight Diagnostics announces $58.75 Million Series B financing led by Foresite Capital to commercialize ultrasensitive liquid biopsy MRD testing platform